Co-Diagnostics, Inc. Investors: Company Under Investigation by Portnoy Law Firm | New


Investors canContactthe toll-free law firm to learn more about recovering their losses

​LOS ANGELES, Aug. 23, 2022 (GLOBE NEWSWIRE) — Portnoy Law Firm advises investors of Co-Diagnostics, Inc. (“Co-Dx” or the “Company”) (NASDAQ: CODX) that the firm has launched an investigation into possible securities fraud and may file a class action lawsuit on behalf of investors. Co-Diagnostics investors who have lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone at 844-767-8529 or by email: [email protected], to discuss their legal rights, or click here to join the case via Portnoy Law Firm can provide a free case assessment and discuss options for investors to pursue claims to recover their losses.

On August 11, 2022, Co-Dx shocked investors when the company issued a press release and filed a report with the United States Securities and Exchange Commission that disclosed its financial results for the quarter ended June 30, 2022. The company disclosed revenue of $5.0 million. for the quarter ended June 30, 2022, down from $27.4 million in the prior year period, a decline of nearly 82%. The Company primarily attributed the decline to lower demand for the Logix Smart™ COVID-19 test.

On this news, Co-Dx’s common stock price fell $1.98 per share, or 30.65%, to close at $4.48 per share on August 12, 2022.

Please visit our website to view more information and submit your transaction information.

Portnoy Law Firm represents investors in the prosecution of claims caused by corporate wrongdoing. The company’s founding partner has recovered more than $5.5 billion for harmed investors. Lawyer advertisement. Prior results do not guarantee similar results.

Lesley F. Portnoy, Esq.

Admitted to the CA and NY Bar

[email protected]


Lawyer advertisement

Copyright 2022 GlobeNewswire, Inc.


Comments are closed.